News | Oncology Information Management Systems (OIMS) | April 18, 2017

RaySearch, MD Anderson Collaborate on Development of RayCare

Agreement will allow clinical implementation of next-generation oncology information system across all of MD Anderson’s Greater Houston sites

RaySearch and MD Anderson Collaborate on Development of RayCare

April 18, 2017 — The University of Texas MD Anderson Cancer Center in Houston, Texas, will collaborate with RaySearch on the development of RayCare, the next-generation oncology information system. The agreement covers all of MD Anderson’s sites in the Greater Houston area, including five regional cancer centers. One goal of the collaboration is to enable clinical implementation of RayCare in a complex and large-scale environment.  

MD Anderson is one of the world’s largest cancer centers and a global leader in clinical research. The center treats around 130,000 patients per year and has over 20,000 employees. The scale of its operations make efficiency and safety key priorities, and these will be significant strengths of the RayCare system.

RayCare is designed to unify and consolidate the different software systems that are commonly in operation, including systems for medical oncology, radiation oncology and surgical oncology.  Integrating the varied activities in these workflows saves time, reduces complication and minimizes the risk of errors that can occur when transferring information between systems. Potential benefits for patients include a smoother treatment experience and better continuity of care.

This is the next step in a strong strategic collaboration that combines the research and development strengths of MD Anderson and RaySearch, with the aim of converting research findings into practical solutions that can be brought to market quickly for the benefit of cancer clinics everywhere. MD Anderson has also started using RayStation to generate clinical treatment plans. This is the first phase of a planned clinical rollout that follows extensive training of the clinical teams. RayStation and RayCare are designed to integrate seamlessly, paving the way for even greater gains.

For more information: www.raysearchlabs.com

Related Content

Radiology, radiation therapy, PACS, Enterprise image, X-ray, DR Systems, CT, MRI, contrast, ultrasound, VNA, product comparisons, comparison charts on ITN magazine.
Feature | February 17, 2021
Imaging Technology News (ITN) maintains more than 40
Immunotherapy-based precision medicine clinical trials being developed

Getty Images

News | Prostate Cancer | February 16, 2021
February 16, 2021 — Black men die more often of prostate cancer yet, paradoxically, have greater survival benefits fr
Real Time Imaging Technologies LLC iannounced that it has received U.S. Patent No. 10,898,070 IMAGING APPARATUS AND METHODS which covers the company’s methods for incorporating microlens into X-ray imaging detectors that enables significantly lower radiation dose without compromising image resolution.

Getty Images

News | Radiation Dose Management | February 05, 2021
February 5, 2021 — 

Images in 69-year-old man with biopsy-confirmed Gleason score 7 (3+4) prostate cancer. (a) Pretreatment axial T2-weighted fast spin-echo MRI scan (repetition time msec/echo time msec, 3820/97) shows tumor in midline anterior transition zone (arrow). (b) Intraoperative MRI scan shows contoured rectal wall (red line), prostate margin (blue outline), and region of interest (orange outline). Because the urethra was included in planned treatment volume, a suprapubic catheter was placed for continuous bladder drainage during treatment. (c) Intraoperative MRI scan shows focused ultrasound beam path (blue) overlaid on treatment plan. Rectangles illustrate each sonication spot. (d) Thermal map image obtained during treatment with heat deposition color coded in red overlaid on sonication spot. (e) Axial gadopentetate dimeglumine-enhanced MRI scan (230/2.97) obtained immediately after treatment shows devascularized ablated volume (arrows). (f) Corresponding T2-weighted fast spin-echo MRI scan (3820/97) at 5 months after ablation shows complete involution of transition zone. All seven cores from treatment area margins were negative for cancer at biopsy. Image courtesy of the Radiological Society of North America

News | Prostate Cancer | February 05, 2021
February 5, 2021 — A technique that delivers...
Ludwig Chicago Co-director Ralph Weichselbaum and Kaiting Yang, a postdoctoral researcher in Weichselbaum's lab.

Ludwig Chicago Co-director Ralph Weichselbaum and Kaiting Yang, a postdoctoral researcher in Weichselbaum's lab. Image courtesy of Ludwig Cancer Research

News | Radiation Therapy | January 28, 2021
January 28, 2021 — A study led by Ludwig Chicago